开发可信人工智能模型预测血管疾病进展:VASCUL-AID-RETRO研究方案
VASCUL-AID-RETRO研究方案拟从多个欧洲中心回顾性收集2015至2024年5000例腹主动脉瘤和6000例外周动脉疾病患者的多模态数据,开发可信人工智能模型预测疾病进展和心血管事件。模型将先按单一模态分别开发,再整合为多模态预测模型,并计划在前瞻性队列VASCUL-AID-PRO研究中进行内部验证。
要点
- 拟纳入5000例腹主动脉瘤和6000例外周动脉疾病患者的多模态数据。
- 数据包括临床记录、影像、蛋白质组学和基因组学,来源于电子健康档案、生物样本库和登记库。
- 模型将先按单一模态分别开发,再整合为多模态预测模型。
核心结论
- VASCUL-AID-RETRO研究将利用先进人工智能技术并整合临床、影像和多组学数据,预测腹主动脉瘤和外周动脉疾病的进展及心血管事件。
研究设计与样本
- VASCUL-AID-RETRO研究方案拟从VASCUL-AID联盟的多个欧洲中心回顾性收集2015至2024年电子健康档案中5000例腹主动脉瘤和6000例外周动脉疾病患者的数据。
- 回顾性收集的数据将用来自现有生物样本库和登记库的额外数据加以补充。
- 将收集包括临床记录、放射影像、蛋白质组学和基因组学在内的多模态数据以开发人工智能模型。
- 将通过关键意见领袖会议制定两种疾病的共识性临床参数变量列表和核心结局集。
- 将分析现有生物样本库的血液、血浆和组织样本的蛋白质组学和基因组学变异。
关键数值与推荐
- 将基于分割的腹主动脉瘤和外周动脉动脉几何形态训练人工智能模型,估算血流动力学参数以量化疾病进展。
- 最初将按每种模态分别开发风险预测模型,随后将所有数据合并作为多模态预测模型的输入。
- 开发出的模型将用前瞻性数据进一步调整,并在前瞻性队列VASCUL-AID-PRO研究中进行内部验证。
临床怎么用
- VASCUL-AID-RETRO研究旨在通过开发人工智能驱动的多模态预测模型改善血管外科临床实践,促进个体化医疗。
- 这些模型有望为疾病进展和心血管事件提供准确的风险分层。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Abdominal aortic aneurysms (AAAs) and peripheral artery disease (PAD) are two vascular diseases with a significant risk of major adverse cardiovascular events and mortality. A challenge in current disease management is the unpredictable disease progression in individual patients. The VASCUL-AID-RETRO study aims to develop trustworthy multimodal predictive artificial intelligence (AI) models for multiple tasks including risk stratification of disease progression and cardiovascular events in patients with AAA and PAD. METHODS: The VASCUL-AID-RETRO study will collect data from 5000 AAA and 6000 PAD patients across multiple European centers of the VASCUL-AID consortium using electronic health records from 2015 to 2024. This retrospectively-collected data will be enriched with additional data from existing biobanks and registries. Multimodal data, including clinical records, radiological imaging, proteomics, and genomics, will be collected to develop AI models predicting disease progression and cardiovascular risks. This will be done while integrating the international ethics guidelines and legal standards for trustworthy AI, to ensure a socially-responsible data integration and analysis. PROPOSED ANALYSES: A consensus-based variable list of clinical parameters and core outcome set for both diseases will be developed through meetings with key opinion leaders. Blood, plasma, and tissue samples from existing biobanks will be analyzed for proteomic and genomic variations. AI models will be trained on segmented AAA and PAD artery geometries for estimation of hemodynamic parameters to quantify disease progression. Initially, risk prediction models will be developed for each modality separately, and subsequently, all data will be combined to be used as input to multimodal prediction models. During all processes, data security, data quality, and ethical guidelines and legal standards will be carefully considered. As a next step, the developed models will be further adjusted with prospective data and internally validated in a prospective cohort (VASCUL-AID-PRO study). CONCLUSION: The VASCUL-AID-RETRO study will utilize advanced AI techniques and integrate clinical, imaging, and multi-omics data to predict AAA and PAD progression and cardiovascular events. CLINICAL TRIAL REGISTRATION: The VASCUL-AID-RETRO study is registered at www.clinicaltrials.gov under the identification number NCT06206369. CLINICAL IMPACT: The VASCUL-AID-RETRO study aims to improve clinical practice of vascular surgery by developing artificial intelligence-driven multimodal predictive models for patients with abdominal aortic aneurysms or peripheral artery disease, enhancing personalized medicine. By integrating comprehensive data sets including clinical, imaging, and multi-omics data, these models have the potential to provide accurate risk stratification for disease progression and cardiovascular events. An innovation lies in the extensive European data set in combination with multimodal analyses approaches, which enables the development of advanced models to facilitate better understanding of disease mechanisms and progression. For clinicians, this means that more precise, individualized treatment plans can be established, ultimately aiming to improve patient outcomes.
引用
- Rijken L, Zwetsloot S, Smorenburg S, et al. Developing Trustworthy Artificial Intelligence Models to Predict Vascular Disease Progression: the VASCUL-AID-RETRO Study Protocol. J Endovasc Ther. 2025. PMID: 39921236. doi:10.1177/15266028251313963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。